Valuation: Resonate Blends Inc.

Market Cap 834K 733K 681K 625K 1.17M 80.32M 1.19M 8.09M 3.16M 39.49M 3.13M 3.06M 137M P/E 2023
-0.56x
P/E 2024 -0.16x
Enterprise Value 4.68M 4.11M 3.83M 3.51M 6.6M 451M 6.7M 45.43M 17.75M 222M 17.58M 17.2M 767M EV / Sales 2023
211x
EV / Sales 2024 2.22x
Free-Float
98.5%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer 56 2025-03-04
Director TitleAgeSince
Chairman 65 -
Director/Board Member 56 2024-03-13
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-2.46% - - 195K
+0.63%-3.06%+16.18%-9.78% 66.32B
+1.23%+2.80%+37.51%+202.14% 52.6B
+10.08%+51.80%+51.80%+51.80% 43.27B
-1.32%-7.38%-57.63%-57.10% 38.64B
+0.78%-1.84%+52.49%-27.01% 29.62B
+0.84%+0.36%+66.93%+85.42% 23.31B
-5.17%-12.54%+58.98%-56.04% 22.62B
-1.21%+1.12%+1.98%+170.93% 20.22B
-0.22%-0.95%+61.97%+123.78% 16.29B
Average +1.16%-1.31%+32.25%+53.79% 34.77B
Weighted average by Cap. +1.68%-0.40%+27.36%+49.26%

Financials

2023 2024
Net sales 16.47K 14.46K 13.45K 12.34K 23.19K 1.59M 23.55K 160K 62.4K 780K 61.82K 60.49K 2.7M 1.9M 1.67M 1.55M 1.42M 2.67M 183M 2.71M 18.39M 7.19M 89.78M 7.12M 6.96M 310M
Net income -1.42M -1.24M -1.16M -1.06M -1.99M -136M -2.02M -13.73M -5.37M -67.04M -5.32M -5.2M -232M -2.13M -1.87M -1.74M -1.6M -3M -205M -3.05M -20.69M -8.08M -101M -8.01M -7.84M -349M
Net Debt 2.51M 2.2M 2.05M 1.88M 3.53M 242M 3.59M 24.33M 9.51M 119M 9.42M 9.22M 411M 3.85M 3.38M 3.14M 2.89M 5.42M 371M 5.5M 37.34M 14.59M 182M 14.45M 14.14M 630M
Logo Resonate Blends Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. The Company is engaged in the field of regenerative medicine using biologic-based products. Its products are intended to market under third-party label exemptions. The Company is focused on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. It is licensed under a patent-pending application to market a dual-acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Its products are being developed for consumer and professional markets.
Employees
-